Content about Human reproduction

April 2, 2014

A daily low dose of aspirin does not appear to prevent subsequent pregnancy loss among women with a history of one or two prior pregnancy losses, according to researchers at the National Institutes of Health.

BETHESDA, Md. — A daily low dose of aspirin does not appear to prevent subsequent pregnancy loss among women with a history of one or two prior pregnancy losses, according to researchers at the National Institutes of Health.

However, in a smaller group of women who had experienced a single recent pregnancy loss, aspirin increased the likelihood of becoming pregnant and having a live birth.

March 26, 2014

Actavis and Valeant Pharmaceuticals International announced that the Food and Drug Administration approved the new drug application for Metronidazole 1.3% vaginal gel. The antibiotic is used for the treatment of bacterial vaginosis, an infection caused by an imbalance in the normal bacteria of vagina.

DUBLIN and LAVAL, Quebec — Actavis and Valeant Pharmaceuticals International announced that the Food and Drug Administration approved the new drug application for Metronidazole 1.3% vaginal gel.

The antibiotic is used for the treatment of bacterial vaginosis, an infection caused by an imbalance in the normal bacteria of vagina. It's the most common vaginal infection in women ages 15 years to 44 years. Metronidazole 1.3% provides a single-dose treatment that is packaged in a pre-filled disposable applicator.

March 4, 2014

Church & Dwight on Tuesday announced that the Food and Drug Administration has cleared the First Response Gold Digital Pregnancy Test to determine if a woman is pregnant up to six days before her missed period and with more than 99% accuracy from the day of her expected period.

EWING, N.J. — Church & Dwight on Tuesday announced that the Food and Drug Administration has cleared the First Response Gold Digital Pregnancy Test to determine if a woman is pregnant up to six days before her missed period and with more than 99% accuracy from the day of her expected period. In addition, the First Response Early Result Pregnancy Test, which was previously cleared to determine if a woman is pregnant up to six days before her missed period, also has been FDA-cleared to detect pregnancy with more than 99% accuracy from the day of her expected period. 

February 11, 2014

A study conducted by Beijing Friendship Hospital published Tuesday found that condoms may help prevent vaginal infection.

NEWPORT BEACH, Calif. — A study conducted by Beijing Friendship Hospital published Tuesday found that condoms may help prevent vaginal infection.

The study examined 164 married women, ages 18 to 45, all in good health. Seventy-two of them were using condoms for birth control. The women using condoms were found to have higher levels of beneficial bacteria or lactobacillus, which is thought to block harmful bacteria from causing odor and infection.

December 26, 2013

Sales of personal lubricants were down 5.2% to $207.5 million in sales for the 52 weeks ended Oct. 6, according to IRI across total U.S. multi-outlets.

Sales of personal lubricants were down 5.2% to $207.5 million in sales for the 52 weeks ended Oct. 6, according to IRI across total U.S. multi-outlets. A big part of that decrease is due to new Food and Drug Administration regulations that require lubricant manufacturers to submit a 501k medical device application for approval.

November 15, 2013

The Food and Drug Administration has approved an OTC personal lubricant that helps couples conceive more easily.

CHICAGO — The Food and Drug Administration has approved an OTC personal lubricant that helps couples conceive more easily.

Sasmar announced Friday the FDA approval of Conceive Plus, described as an isotonic, fertility-friendly personal lubricant that helps increase a woman's chances of getting pregnant naturally. The patent-pending formula is pH balanced to mimic fertile fluids and semen and contains minerals helpful to fertilization.

October 8, 2013

The Food and Drug Administration has approved a new treatment for hot flashes and the prevention of osteoporosis, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for hot flashes and the prevention of osteoporosis, the agency said.

The FDA announced the approval of Duavee (conjugated estrogens; bazedoxifene), made by Pfizer. The drug is for women who suffer from moderate to severe hot flashes associated with menopause, and is also designed to prevent osteoporosis after menopause.

August 28, 2013

Swiss Precision Diagnostics recently launched its Clearblue Advanced Pregnancy Test with Weeks Estimator — the first and only pregnancy test that also provides an estimate of time since ovulation for women testing pregnant — into the U.S. marketplace.

PETIT LANCY, Switzerland — Swiss Precision Diagnostics recently launched its Clearblue Advanced Pregnancy Test with Weeks Estimator — the first and only pregnancy test that also provides an estimate of time since ovulation for women testing pregnant — into the U.S. marketplace.

August 5, 2013

A new treatment for bacterial infections of the vagina is now available, the drug's manufacturer said.

ST. LOUIS — A new treatment for bacterial infections of the vagina is now available, the drug's manufacturer said Monday.

K-V Pharmaceutical Co. subsidiary Ther-Rx Corp. announced the availability of Clindesse (clindamycin phosphate), saying wholesalers have ordered and received it and are distributing it to retail pharmacies. The drug is used to treat bacterial vaginosis in women who are not pregnant. BV results from an overgrowth of several bacterial species and is the most common vaginal infection in women of childbearing age.

July 31, 2013

CPG manufacturers may have another reason to ensure their products can be advertised as "BPA-free." Exposure to BPA (Bisphenol-A) could be a contributing factor to why some couples are having difficulty conceiving, reported Catherine Racowsky, director of the Assisted Reproductive Technologies Laboratory at Brigham and Women's Hospital and author of the BPA study.

BOSTON — CPG manufacturers may have another reason to ensure their products can be advertised as "BPA-free." Exposure to BPA (Bisphenol-A) could be a contributing factor to why some couples are having difficulty conceiving, reported Catherine Racowsky, director of the Assisted Reproductive Technologies Laboratory at Brigham and Women's Hospital and author of the BPA study. 

July 9, 2013

Sylk USA introduced its new Sylk personal lubricant, a water-based lubricant made from New Zealand kiwi vine extract.

PHOENIX — Sylk USA on Tuesday introduced its new Sylk personal lubricant, a water-based lubricant made from New Zealand kiwi vine extract. The intimacy health product is being marketed as both gentle on the planet and gentle on a woman's sensitive vaginal environment with a neutral pH balance. 

Additionally, since it's water-based, it can be safely used with latex condoms, the company noted.

May 6, 2013

Swiss Precision Diagnostics unveiled the new Clearblue Advanced Pregnancy Test with Weeks Estimator at the 61st Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists here.

NEW ORLEANS — Swiss Precision Diagnostics on Monday unveiled the new Clearblue Advanced Pregnancy Test with Weeks Estimator at the 61st Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists here. The latest home pregnancy test kit not only tells a woman if she is pregnant but also estimates the number of weeks since ovulation. 

May 3, 2013

Women who take low-dose oral contraceptives may be at increased risk of chronic pelvic-pain symptoms and pain during sexual climax, according to a new study.

SAN DIEGO — Women who take low-dose oral contraceptives may be at increased risk of chronic pelvic-pain symptoms and pain during sexual climax, according to a new study.

The study, scheduled for presentation to reporters at the American Urological Association's annual scientific meeting in San Diego on Tuesday, was conducted by researchers at New York University and the Waitemata District Health Board in Auckland, New Zealand, compared CPPS in young women who used oral contraceptives with the condition in those who didn't.

April 9, 2013

Procter & Gamble launched Clearblue Advanced Digital Ovulation Test, the only ovulation test that can identify a woman’s four best days to get pregnant, two more days than any other test on the market, according to the company.

CINCINNATI — Procter & Gamble on Tuesday launched Clearblue Advanced Digital Ovulation Test, the only ovulation test that can identify a woman’s four best days to get pregnant, two more days than any other test on the market, according to the company. And in support of the launch, former Dallas Cowboys cheerleader and veteran of ABC's "Dancing with the Stars" Melissa Rycroft will serve as spokeswoman. 

April 1, 2013

E.p.t, creator of the original home pregnancy test, has partnered with the American Fertility Association to support the vast community of those who are actively trying to conceive during National Infertility Awareness Month this April.

TREVOSE, Pa. — E.p.t, creator of the original home pregnancy test, has partnered with the American Fertility Association to support the vast community of those who are actively trying to conceive, or TTC, during National Infertility Awareness Month this April.

February 26, 2013

The Food and Drug Administration has approved a drug for postmenopausal women who experience pain during sex.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug for postmenopausal women who experience pain during sex.

The agency announced the approval of Shionogi's Osphena (ospemifene) for women with moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause associated with declining levels of estrogen hormones.

January 30, 2013

A patch for treating menopause that the manufacturer calls the smallest is now available.

NEW YORK — A patch for treating menopause that the manufacturer calls the smallest is now available.

Noven Pharmaceuticals announced the availability of Minivelle (estradiol) transdermal system in pharmacies. The patch, which the Food and Drug Administration approved in October 2012, is designed for treating hot flashes and night sweats in women with menopause.

The patch has a surface area nearly the same as a dime at its lowest strength of 0.0375 mg-per-day and is 34% smaller than Noven's Vivelle-Dot patch, the company said.

November 28, 2012

Regional life sciences association Biocom has introduced a new eco-friendly alternative to sanitary napkins and tampons. Enter FemmyCycle, a product from member FemCap.

SAN DIEGO — Regional life sciences association Biocom has introduced a new eco-friendly alternative to sanitary napkins and tampons. Enter FemmyCycle, a product from member FemCap.

The FemmyCycle was granted clearance by the U.S. Food and Drug Administration on Nov. 16. FemmyCycle creator Alfred Shihata is familiar with developing feminine products. His FDA-approved FemCap is one of the few hormone-free, woman-controlled contraceptive methods available.

September 21, 2012

The National Advertising Division on Thursday recommended that Church & Dwight discontinue its claim that the company’s First Response digital ovulation test is the “first and only test to predict ovulation based on your unique LH hormone level.”

NEW YORK — The National Advertising Division on Thursday recommended that Church & Dwight discontinue its claim that the company’s First Response digital ovulation test is the “first and only test to predict ovulation based on your unique LH hormone level.”

The claim, which appeared on product packaging and on the company’s website, was challenged by SPD Swiss Precision Diagnostics, the maker of the Clearblue DOT, a competing digital ovulation test product.

June 29, 2012

The Food and Drug Administration has accepted a regulatory approval application for a drug made by Shionogi for treating vulvar and vaginal atrophy due to menopause.

FLORHAM PARK, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a drug made by Shionogi for treating vulvar and vaginal atrophy due to menopause.

Shionogi, the U.S. division of Japanese drug maker Shionogi & Co., said Wednesday that the FDA had accepted for review its application for ospemifene, which the company touts as potentially the first oral alternative to vaginal estrogen treatments.

March 15, 2012

The Food and Drug Administration has approved a drug that the manufacturer called the first oral contraceptive that also treats heavy menstrual bleeding.

WAYNE, N.J. — The Food and Drug Administration has approved a drug that the manufacturer called the first oral contraceptive that also treats heavy menstrual bleeding.

Bayer HealthCare Pharmaceuticals announced Wednesday the approval of Natazia (estradiol valerate and estradiol valerate and dienogest) tablets for heavy menstrual bleeding not caused by any conditions of the uterus. The drug was originally approved as an oral contraceptive in May 2010.

March 2, 2012

A generic drug maker has launched its version of an Abbott Labs drug.

JERUSALEM — A generic drug maker has launched its version of an Abbott Labs drug.

Teva Pharmaceutical Industries said it launched progesterone capsules in the 100-mg and 200-mg strengths, a generic version of Prometrium.

Prometrium is indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogen tablets. The drug also is indicated for use in secondary amenorrhea.

For the 12 months ended Jan. 31, Prometrium had sales of approximately $198 million, according to IMS Health data.

November 10, 2011

Kimberly-Clark on Wednesday recalled a limited number of a Kotex product distributed to specific stores in the United States.

DALLAS — Kimberly-Clark on Wednesday recalled a limited number of a Kotex product distributed to specific stores in the United States.

July 22, 2011

A study slated to appear in the Journal of Clinical Endocrinology & Metabolism, a publication of the Endocrine Society, found that adolescent girls that take the diabetes drug metformin may prevent or delay the development of polycystic ovary syndrome, a common cause of infertility.

NEW YORK — A study slated to appear in the Journal of Clinical Endocrinology & Metabolism, a publication of the Endocrine Society, found that adolescent girls that take the diabetes drug metformin may prevent or delay the development of polycystic ovary syndrome, a common cause of infertility.

June 14, 2011

Many American consumers are in favor of oral contraceptive coverage by both private and government-subsidized health insurance plans, according to a Thomson Reuters-National Press Radio Health Poll released Friday.

ANN ARBOR, Mich. — Many American consumers are in favor of oral contraceptive coverage by both private and government-subsidized health insurance plans, according to a Thomson Reuters-National Press Radio Health Poll released Friday.

"Our survey findings provide a benchmark for public sentiment on issues that are continually dividing lawmakers, businesspeople and healthcare professionals," said Raymond Fabius, chief medical officer at the healthcare business of Thomson Reuters.